Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 15;41(6):1296–1306. doi: 10.1200/JCO.22.00232

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Performance of QCIGISH test in the blinded prospective validation cohort. (A) Distribution of histopathologically benign and malignant cases in different ultrasound imaging categories. (B) Distribution of histopathologically benign and malignant cases in different Bethesda cytopathology categories. (C) Sensitivity, specificity, PPV, and NPV of the QCIGISH test in the blinded prospective validation study. Distribution of histopathologically benign and malignant cases in QCIGISH-negative and QCIGISH-positive groups for (D) Bethesda II, (E) Bethesda III and IV, (F) Bethesda V, and (G) Bethesda IV categories. Histopathologic benign and malignant diagnoses were confirmed by postsurgical thyroid examination in all cases. ACR TI-RADS, American College of Radiology Thyroid Imaging, Reporting, and Data System; NED, no evidence of disease; NPV, negative predictive value; PPV, positive predictive value; QCIGISH, quantitative chromogenic imprinted gene in situ hybridization.